The Role of Redox-Regulating Enzymes in Inoperable Breast Cancers Treated with Neoadjuvant Chemotherapy

Table 3

Tumor properties. Estrogen receptor (ER), progesterone receptor (PR), Ki-67, and HER2 expressions and grade are reported as in postoperative PAD. If unavailable in postoperative PPS, the assessment from the core needle biopsy is reported.

	Number of patients	Percentage or range
Response to NACT	52	100
Complete response	6	11.3
Partial response	44	83.0
Stable disease	2	3.8
Progression	0	0
Histopathological grade	53	100
Grade 1	1	1.9
Grade 2	19	35.8
Grade 3	19	35.8
No information or no viable cancer cells	14	26.4
ER status	53	100
Negative (0%)	9	17.0
Weak (1–9%)	8	15.1
Moderate (10–59%)	2	3.8
High (>59%)	34	64.2
PR status	53	100
Negative (0%)	23	43.4
Weak (1–9%)	5	9.4
Moderate (10–59%)	3	5.6
High (>59%)	22	41.5
Ki-67 status	53	100
Negative (<5%)	6	11.3
Weak (5–14%)	12	22.6
Moderate (15–30%)	12	22.6
High positive (>30%)	22	41.5
No information or no viable cancer cells	1	1.9
HER2 status	53	100
Negative	37	69.8
Positive (confirmed with CISH)	16	30.2
Median number of metastatic lymph nodes	2.0	0–20
Distant metastases at the time of diagnosis	53	100
Absent	43	81.1
Present	10	18.9

The information of pre-NACT tumor size was missing from one patient.